Skip to content

Schering-Plough SGP Operating Income

Operating Income at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$642.9M+8.7%
Glaukos logo
GlaukosGKOS
-$19.86M+4.0%
AbbVie logo
AbbVieABBV
$3.99B+6.9%
Bausch + Lomb logo
Bausch + LombBLCO
$33M+140%
HRO
HarrowHROW
-$22.08M-96.6%
Johnson & Johnson logo
Johnson & JohnsonJNJ

Other financials

Income statement

See full
Net income-$13.8M-56.6%
EPS (diluted)-$0.69+82.6%

Balance sheet

See full
Cash & equivalents$238.9M+312%
Total debt$1.6M
Total equity$250.1M+463%
Total assets$258.4M

Cash flow

See full
Operating cash flow-$13.5M-65.2%
CapEx$676.0K+312%
Free cash flow-$14.2M-70.0%

Valuation

See full
Market cap$744.23M-23.4%
Enterprise value$506.93M

Returns & leverage

See full
Return on equity-34.3%
Debt / equity
Current ratio38×

Where this comes from

Reported directly by Schering-Plough in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Schering-Plough’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schering-Plough's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schering-Plough's operating income?
Schering-Plough (SGP) reported operating income of -$15.41M in Q1 2026.
How has Schering-Plough's operating income changed year-over-year?
Schering-Plough's operating income decreased by 107.6% year-over-year, from -$7.42M to -$15.41M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.